Given Jiangsu Nhwa Pharmaceutical's significant investment and lucrative return rate, earnings are projected to rise substantially. Despite uncertainty in analysts' projections, performance is deemed satisfactory, fueling expectations for accelerated earnings growth due to low payout ratios.